Clinical Trial Update: Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058 [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update evaluating immunogenicity and reactogenicity of Boostrix ten years after prior booster vaccination.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acellular Pertussis
• Diphtheria
• Tetanus

Drugs mentioned

• Boostrix (Diphtheria, Tetanus, and Acellular Pertussis Vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Acellular Pertussis, Tetanus | Phase 4 | Status: COMPLETED | Results posted: 2019-01-15